Madrigal Pharmaceuticals, Inc. (MDGL) Social Stream
MADRIGAL PHARMACEUTICALS INC (MDGL) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering MDGL.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-12 | 11 | $203 | $145 | $174.5 | $278.41 | -37.32% |
| 2021-12-30 | 10 | $203 | $145 | $173.714 | $278.41 | -37.6% |
| 2022-02-25 | 9 | $203 | $131 | $167.571 | $278.41 | -39.81% |
| 2022-05-11 | 10 | $203 | $129 | $161.5 | $278.41 | -41.99% |
| 2022-05-12 | 10 | $203 | $129 | $156.25 | $278.41 | -43.88% |
| 2022-05-26 | 9 | $203 | $129 | $156.25 | $278.41 | -43.88% |
| 2022-08-04 | 9 | $203 | $75 | $149.25 | $278.41 | -46.39% |
| 2022-09-02 | 8 | $203 | $75 | $149.25 | $278.41 | -46.39% |
| 2022-11-10 | 7 | $203 | $75 | $141.875 | $278.41 | -49.04% |
| 2022-12-07 | 8 | $203 | $75 | $141.875 | $278.41 | -49.04% |
| 2022-12-20 | 11 | $375 | $92 | $250.3 | $278.41 | -10.1% |
| 2022-12-21 | 11 | $375 | $194 | $289.75 | $278.41 | 4.07% |
| 2023-01-05 | 11 | $390 | $194 | $296.25 | $278.41 | 6.41% |
| 2023-02-24 | 11 | $390 | $194 | $303 | $278.41 | 8.83% |
| 2023-02-27 | 11 | $390 | $194 | $305.083 | $278.41 | 9.58% |
| 2023-05-09 | 12 | $390 | $194 | $312.583 | $278.41 | 12.27% |
| 2023-05-15 | 12 | $396 | $194 | $319.833 | $278.41 | 14.88% |
| 2023-05-16 | 12 | $396 | $194 | $324 | $278.41 | 16.38% |
| 2023-05-19 | 12 | $396 | $224 | $326.5 | $278.41 | 17.27% |
The Trend in the Analyst Price Target
Over the past 36 months, MDGL's average price target has gone up $152.36.
Over the past 45 weeks, MDGL's average upside potential has been 43.89%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2022-12-07 | 8 | 203 | 75 | 141.875 | 67.36 | 110.62% |
| 2023-01-05 | 11 | 390 | 194 | 296.250 | 271.71 | 9.03% |
| 2023-02-08 | 11 | 390 | 194 | 303.000 | 259.92 | 16.57% |
| 2023-05-07 | 12 | 390 | 194 | 312.583 | 306.37 | 2.03% |
| 2023-05-19 | 12 | 396 | 224 | 326.500 | 276.61 | 18.04% |
MDGL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 10 | 0 | 2 | 0 | 0 | 12 |
The Trend in the Broker Recommendations
Over the past 17 months, MDGL's average broker recommendation rating improved by 0.07.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for MDGL as an investment opportunity.
- MDGL has a greater average analyst price target than 2429.06% of stocks in the mid market cap category.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, MADRIGAL PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is higher than 163.95% of them.
- In the context of stocks in the mid market cap category, MADRIGAL PHARMACEUTICALS INC's number of analysts covering the stock is greater than 1904.17% of them.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, MADRIGAL PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1562.42% of them.
Stocks similar to MADRIGAL PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are MGNX, CYRX, and CMRX.
View All Top Stocks by Price Target
Is MDGL a Buy, Hold or Sell? See the POWR Ratings now!